The global radiation dermatitis treatment market size is estimated to be valued at USD 569.3 Million in 2025. It is projected to reach a valuation of USD 822.7 Million by 2032, exhibiting a CAGR of 5.4% throughout the forecast period (2025-2032).
Radiation dermatitis is a skin condition that occurs as a side effect of receiving radiation therapy. The increasing number of cancer cases and the radiation therapy treatment for cancer are the major factors driving market growth. Innovations in radiation dermatitis management and the use of barriers films for reducing the severity of radiation are expected to facilitate market growth.
However, high treatment costs can hinder market growth.
Key Market Insights
The radiation dermatitis market is expected to be shaped by advancements in topical formulations and integration of biologic compounds.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/radiation-dermatitis-treatment-market
Radiation Dermatitis Treatment Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 569.3 Million |
|
Estimated Value by 2032 |
USD 822.7 Million |
|
Growth Rate |
5.4% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD million) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The evolution of supportive oncodermatology, driven by the emergence of new cancer treatments, is a key driver of the radiation dermatitis treatment market. These include epidermal growth factor receptor (EGFR) inhibitors and topical formulations for mitigating the effects of radiation. Huge advances in cancer therapeutics and the alarming prevalence of cancers among elderly patients can drive this trend in the market. This is supported by a study published by Wake Forest University Health Sciences on March 17, 2025, on the efficacy of KeraStat cream for radiation dermatitis. KeraStat cream, manufactured by KeraNetics Inc., is designed to reduce the severity of adverse skin reactions on the applied region.
Pilot studies on interventions such as Hyperbaric Oxygen Therapy (HBOT) and photobiomodulation (PBM) therapy for the alleviation of radiation-induced dermatitis can provide relief to cancer patients. The large number of cases of acute radiation dermatitis to chronic radiation dermatitis in cancer patients highlights the necessity of these treatments as part of radiation dermatitis management.
Market Opportunity
Photobiomodulation (PBM) Therapy
Photobiomodulation, also known as red light therapy, is a treatment approach gaining consensus among healthcare professionals for the management of radiation dermatitis. Its long-term safety and its efficacy in the treatment of acute radiation dermatitis are indicators of its huge potential. A panel of clinicians in the U.S. recently came together on April 23, 2025, to provide guidelines on its use on patients. PBM can improve tissue regeneration and increase collagen production.
Market Challenges
Lack of Reimbursement Coverage for Radiation Dermatitis
The lack of reimbursement coverage for the disease by major hospital chains can prove to be a challenge to market growth. The absence of a unified grading system for the assessment of the severity of the disease, ranging from mild erythema to moist desquamation, has resulted in inconsistent product adoption across healthcare institutions.
Analyst’s View
Recent Developments
Lutris Pharma announced the results of its trial of the compound, LUT014 gel, on June 17, 2025. The gel can be used in combination with EFGR inhibitor therapy given to cancer patients.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :